| 词条 | Fosfomycin/tobramycin |
| 释义 |
| type = combo | drug_name = Fosfomycin/tobramycin (FTI) | component1 = Fosfomycin | class1 = Phosphonic acid | component2 = Tobramycin | class2 = Aminoglycoside | component3 = | class3 = | component4 = | class4 = | tradename = | Drugs.com = | MedlinePlus = | licence_EU = | licence_US = | DailyMedID = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | dependency_liability = | routes_of_administration = Inhalation | CAS_number = | CAS_supplemental = | ATCvet = | ATC_prefix = | ATC_suffix = | ATC_supplemental = | PubChem = | PubChemSubstance = | IUPHAR_ligand = | DrugBank = | ChemSpiderID = | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = }}Fosfomycin/tobramycin is a formulation of fosfomycin and tobramycin. Fosfomycin is a phosphonic acid antibiotic active against gram-positive, gram-negative, and anaerobic bacteria. Tobramycin is an aminoglycoside with gram-negative activity. It is an inhaled medication targeting those with cystic fibrosis and is currently being studied by Gilead Sciences the United States Food and Drug Administration and the NIH General Clinical Research Center.[1] See also
References1. ^{{cite journal |vauthors=Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, etal | title=Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection. | journal=Am J Respir Crit Care Med | year= 2011 | volume= 185| issue= 2| pages= 171–8| pmid=22095545 | doi=10.1164/rccm.201105-0924OC | pmc= 3361752}} {{DEFAULTSORT:Fosfomycin tobramycin}} 4 : Aminoglycoside antibiotics|Antibiotics|Phosphonic acids|Epoxides |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。